Cellular immunotherapy researchers have long been focused on tumor infiltrating lymphocytes (TILs). These naturally occurring anti-cancer cells fight—from inside the tumor—against malignant cells. TIL Cell Therapy is currently being evaluated in clinical trials and encouraging study results have been presented and published.

In this episode, hear from two experts in cancer immunotherapy on the exciting potential of TIL Cell Therapy in melanoma and beyond, where cellular immunotherapy fits into the expanding range of cancer immunotherapies, and what community providers need to know.

Guests:

Sigrun Hallmeyer, MD  Medical Director, Advocate Lutheran General Hospital Cancer Service Line Medical Director, Advocate Lutheran General Hospital Cancer Survivorship Program   Co-Director, Medical Research, Advocate AuroraHealth  Park Ridge, IL 

Mark Faries, MD  Co-director, Melanoma Program and Head of Surgical Oncology  The Angeles Clinic & Research Institute  Los Angeles, CA

Related Content:

• ACCC Immuno-Oncology Institute
• What is Tumor Infiltrating Lymphocyte TIL Therapy?
• Cell Therapy with TILs: Training and Taming T Cells to Fight Cancer
• Clinical Trials Using Tumor Infiltrating Lymphocyte Therapy
• Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics
• TIL Therapy Explained by Steven Rosenberg, MD, PhD  
• Tumor-infiltrating lymphocytes show ‘dramatic’ results in metastatic melanoma
• Tumor-infiltrating lymphocyte cell therapy ‘potentially viable’ option for advanced NSCLC